methotrexate has been researched along with Hematologic Malignancies in 126 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (9.52) | 18.2507 |
| 2000's | 50 (39.68) | 29.6817 |
| 2010's | 48 (38.10) | 24.3611 |
| 2020's | 16 (12.70) | 2.80 |
| Authors | Studies |
|---|---|
| Devine, SM; Geller, N; Giralt, S; Heslop, HE; Ho, VT; Horowitz, MM; Jones, RJ; Litzow, MR; Logan, B; Luznik, L; Mendizabal, A; Muffly, L; Nemecek, ER; O'Donnell, L; O'Reilly, RJ; Palencia, R; Pasquini, MC; Perales, MA; Schetelig, J; Shune, L; Soiffer, RJ; Solomon, SR; Vasu, S; Wu, J | 1 |
| Ebid, AIM; El Gammal, MM; Hossam, A; Mahmoud, MA; Mangoud, NOM; Soror, S | 1 |
| Certan, M; Garcia Garrido, HM; Goorhuis, A; Grobusch, MP; Heijmans, J; Wong, G | 1 |
| Hilal, T; Jain, SP | 1 |
| Bucher, C; Dertschnig, S; Finke, J; Gergely, P; Heim, D; Holler, E; Holtick, U; Medinger, M; Oehen, S; Passweg, J; Schanz, U; Socié, G; Stylianou, C; Teshima, T | 1 |
| Al Malki, MM; Alousi, AM; Applegate, K; Bhatt, AS; Bolaños-Meade, J; Clark, W; DiFronzo, NL; Efebera, YA; El Jurdi, N; Elmariah, H; Gooptu, M; Hall, AC; Hamadani, M; Holtan, SG; Horowitz, MM; Jamy, OH; Jones, RJ; Kean, LS; Larkin, KT; Leifer, E; Loren, AW; Martens, MJ; Perales, MA; Reshef, R; Rezvani, AR; Runaas, L; Shaffer, BC; Solh, M; Wu, J; Yao, JM | 1 |
| Aardsma, N; Cabay, RJ; Chowdhery, R; Danciu, OC; Dudek, AZ; Emmadi, R; Fischer, JH; Gaitonde, S; Kothari, R; Liu, LC; Russell, MJ; Venepalli, NK; Zaidi, A | 1 |
| Couban, S; Couture, F; Devins, G; Elemary, M; Foley, R; Gallagher, G; Kerr, H; Kuruvilla, J; Lee, SJ; Moore, J; Nevill, T; Panzarella, T; Popradi, G; Roy, J; Schultz, KR; Szwajcer, D; Toze, C; Walker, I | 1 |
| Estacio, M; Manzi, E; Medina, D; Rosales, M | 1 |
| Amitai, I; El-Saleh, R; Gafter-Gvili, A; Gurion, R; Raanani, P; Rozen-Zvi, B; Rozovski, U; Shepshelovich, D; Shimony, S | 1 |
| Higgins, TA; Kowalski, KE | 1 |
| Heo, BY; Jo, DY; Kwon, J; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yeon, SH; Yun, HJ | 1 |
| Ashizawa, M; Ban, T; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, S; Matsuoka, S; Minakata, D; Murahashi, R; Nagayama, T; Nakano, H; Nakashima, H; Oh, I; Ohmine, K; Sato, K; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Lertvivatpong, N; Monsereenusorn, C; Photia, A; Rujkijyanont, P; Ruktrirong, J; Traivaree, C | 1 |
| Brunello, L; Bruno, B; Busca, A; Butera, S; Cerrano, M; Dellacasa, CM; Faraci, DG; Giaccone, L; Mordini, N; Sorasio, R; Vassallo, S; Zallio, F | 1 |
| Chen, Z; Ding, C; Liu, S; Qu, Q; Wang, G; Wen, F; Zhan, M | 1 |
| Algarra-Algarra, JL; Gómez-Catalán, I; Hernández-Fernández, F; Ibañez-García, Á; Marín-Sánchez, A; Martínez-Fernández, G; Montoya-Morcillo, MC; Romero-Macías, JR | 1 |
| Baker, SD; Bishop, MW; Cheng, C; Jeha, S; Karol, SE; Pappo, AS; Pui, CH; Relling, MV; Rubnitz, JE; Sandlund, JT; Smith, C; Stewart, CF; Yang, W | 1 |
| D'Souza, A; Lee, S; Pasquini, M; Zhu, X | 1 |
| Cabañas-Perianes, V; Díaz-Carrasco, MS; Espuny-Miró, A; Olmos-Jiménez, R; Valderrey-Pulido, M | 1 |
| Bachy, E; Baudouin, A; Bouafia-Sauvy, F; Bourbon, E; Caffin, AG; Gouraud, A; Henin, E; Karlin, L; Ranchon, F; Rioufol, C; Salles, G; Sarkozy, C; Schwiertz, V; Vantard, N; Vial, T | 1 |
| Juvonen, E; Nihtinen, A; Niittyvuopio, R; Ruutu, T; Volin, L | 1 |
| Andrès, CR; Barin-Le Guellec, C; Berthelot, A; Choquet, S; Gyan, E; Marquet, P; Martinez, D; Muhrez, K; Woillard, JB | 1 |
| He, X; Tong, R; Xiao, H; Yao, P; Zhang, R | 1 |
| Cooper, D; DeVeaux, M; Foss, F; Isufi, I; Kim, TK; Perreault, S; Seropian, S; Shlomchik, W; Stahl, M; Zeidan, AM; Zelterman, D | 1 |
| Akahane, D; Gotoh, M; Kobayashi, C; Ohyashiki, JH; Ohyashiki, K; Saitoh, Y; Umezu, T; Yoshizawa, S | 1 |
| Arakawa, Y; Hanada, R; Ikeda, Y; Isobe, K; Koh, K; Mori, M; Oguma, E; Oyama, C; Sasaki, K; Uehara, T; Watanabe, K; Yanagi, M | 1 |
| Huitema, AD; Schellens, JH; Schouten-van Meeteren, AY; van Eijkelenburg, NK; van Hasselt, JG | 1 |
| Boyer, J; Frey, NV; Goldstein, SC; Hexner, EO; June, CH; Kumar, AJ; Levine, BL; Loren, AW; Luger, SM; Porter, DL; Reshef, R; Smith, J; Stadtmauer, EA | 1 |
| Cai, Z; He, J; Huang, H; Lai, X; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhang, J; Zheng, W; Zhu, X | 1 |
| Ahogo, KC; Cliquennois, M; Gosset, P; Lebas, D; Modiano, P; Wantz, M | 1 |
| Addeo, R; D'Angelo, V; Iannotta, A; Ramaglia, M | 1 |
| Bee, PC; Chang, KM; Gan, GG; Lian, LH; Mohamed, Z; Ong, TC; Suthandiram, S; Zain, SM | 1 |
| Abounader, D; Bolwell, B; Copelan, E; Dean, R; Duong, H; Haddad, H; Hamilton, BK; Hanna, R; Hill, BT; Kalaycio, M; Majhail, NS; Rybicki, L; Sobecks, R | 1 |
| Charron, D; Couture, F; Filion, A; Guillemette, C; Lalancette, M; Laverdière, I; Lévesque, É; Loiseau, P; Peffault de Latour, R; Robin, M; Socié, G; Tamouza, R; Tourancheau, A | 1 |
| Champlin, RE; Eapen, M; Horowitz, MM; Lee, SJ; Logan, BR; Perales, MA; Rocha, V; Soiffer, RJ; Zhong, X | 1 |
| Cheng, C; Crews, KR; Jeha, S; Molinelli, AR; Navid, F; Relling, MV; Scott, JR; Stewart, CF; Swanson, HD; Ward, DA; Zhou, Y | 1 |
| Anasetti, C; Beato, F; Betts, BC; Kim, J; Lawrence, HR; Lloyd, MC; Pidala, J; Sagatys, EM; Sebti, SM; Veerapathran, A; Yue, B | 1 |
| Batchelor, TT; Nayak, L; Pentsova, E | 1 |
| Alsina, M; Anasetti, C; Ayala, E; Betts, BC; Fernandez, HF; Field, T; Jim, H; Kharfan-Dabaja, MA; Kim, J; Locke, FL; Mishra, A; Nishihori, T; Ochoa-Bayona, L; Perez, L; Pidala, J; Riches, M | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Wang, FR; Wang, JZ; Wang, Y; Xu, LP; Yan, CH | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Chammas, MJ; Cutler, CS; Glotzbecker, B; Ho, VT; Kim, HT; Koreth, J; Lange, PB; Nikiforow, S; Reynolds, CG; Ritz, J; Soiffer, RJ | 1 |
| Bruce, AJ; Chaudhry, HM; Hashmi, SK; Hogan, WJ; Kremers, WK; Litzow, MR; Patnaik, MS; Phillips, GL; Wolf, RC | 1 |
| Badke, C; Fleming, A; Hijiya, N; Iqbal, A; Khilji, O; Morgan, E; Parhas, S; Weinstein, J | 1 |
| Andritsos, L; Auletta, JJ; Benson, DM; Bingman, A; Blum, W; Bradbury, H; Devine, SM; Efebera, Y; Elder, P; Geyer, S; Hofmeister, C; Jaglowski, S; Kitzler, R; Klisovic, R; Lozanski, G; Muthusamy, N; O'Donnell, LC; Penza, S; Vasu, S | 1 |
| Alshammaa, A; Altaweel, H; Kassem, N; Nader, A; Wilby, KJ; Zahran, N | 1 |
| Chen, D; Ji, L; Liang, L; Ongaro, A; Zhang, Y; Zhao, M; Zhu, Y | 1 |
| Aida, N; Goto, H; Ito, S; Tanaka, F; Tanoshima, R; Tsujimoto, S; Urayama, KY; Yanagimachi, M | 1 |
| Díaz-Carrasco, MS; Espuny-Miró, A; Galera-Miñarro, A; Olmos-Jiménez, R; Pascual-Gazquez, JF | 1 |
| Alyea, EP; Antin, JH; Cutler, C; Ho, V; Kim, HT; Li, S; Soiffer, RJ | 1 |
| Burgaleta, C; de Miguel, D; García-Suárez, J; Gil-Fernández, JJ; Martín, Y | 1 |
| Horibe, K; Kato, K; Kojima, S; Matsumoto, K; Matsuyama, T; Watanabe, N; Yoshimi, A | 1 |
| Chan, JC; Kwong, YL; Yeung, DY | 1 |
| Fujiwara, T; Harigae, H; Ishizawa, K; Kameoka, J; Kohata, K; Miyamura, K; Ohguchi, H; Okitsu, Y; Tomiya, Y; Yamada, MF; Yamamoto, J; Yokoyama, H | 1 |
| Gourde, JA; Khan, SP; Rodriguez, V; Sabapathy, C | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Wang, Y; Xu, LP | 1 |
| Anasetti, C; Appelbaum, FR; Carnevale-Schianca, F; Carpenter, PA; Deeg, HJ; Furlong, T; Kiem, HP; Leisenring, W; Martin, PJ; McDonald, GB; Nash, RA; Schoch, G; Storb, R | 1 |
| Schmiegelow, K | 1 |
| Aldridge, J; Alyea, EP; Antin, JH; Armand, P; Cutler, C; Ho, VT; Kim, HT; Koreth, J; Soiffer, RJ | 1 |
| Bertz, H; Bethge, WA; Bornhäuser, M; Egger, M; Einsele, H; Finke, J; Grishina, O; Heim, DA; Holler, E; Kolb, HJ; Kolbe, K; Koza, V; Linkesch, W; Maertens, JA; Mayer, J; Ottinger, HD; Ruutu, T; Schmoor, C; Schwerdtfeger, R; Socié, G; Stelljes, M; Volin, L; Zander, AR | 2 |
| Alyea, EP; Antin, JH; Armand, P; Cutler, C; Garcia, M; Ho, VT; Kim, HT; Koreth, J; Ritz, J; Soiffer, RJ; Stevenson, KE | 1 |
| Al-Ghamdi, A; Al-Mohareb, F; Al-Sharif, F; Al-Zahrani, H; Aljurf, M; Ayas, M; Chaudhri, N; Mohammed, SY; Nassar, A; Tabbara, KF | 1 |
| Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G | 1 |
| Greenberg, J; Kremer, JM | 1 |
| Chang, YJ; Huang, XJ; Huo, MR; Liu, DH; Liu, KY; Xu, LP; Zhao, XY | 1 |
| Hosone, M; Isobe, Y; Katsuoka, Y; Komatsu, N; Oshimi, K; Shimizu, S; Sugimoto, K; Tsukune, Y; Yasuda, H | 1 |
| Abdelqader, S; Abonour, R; Baute, J; Cornetta, K; Farag, SS; Fausel, CA; Kalsekar, I; Kiel, PJ; Nelson, RP; Robertson, MJ; Rosenbeck, LL; Schwartz, J; Srivastava, S; Sullivan, CK; Vargo, C; Wood, L | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Appelbaum, FR; Carpenter, PA; Deeg, HJ; Flowers, ME; Furlong, T; Inamoto, Y; Kiem, HP; Martin, PJ; Mielcarek, M; Nash, RA; Storb, RF; Storer, BE; Witherspoon, RP | 1 |
| Abboud, M; Arabi, A; Chaiban, J; Daouk, LE; El-Hajj Fuleihan, G; Ghalayini, T; Muwakkit, S | 1 |
| Antin, JH | 1 |
| Aisa, Y; Kato, J; Kunimoto, H; Mori, T; Nakazato, T; Okamoto, S; Ono, Y; Shimizu, T; Yamane, A | 1 |
| Bellesi, S; Chiusolo, P; De Ritis, D; Federica, S; Fianchi, L; Giammarco, S; Giuseppe, L; Hohaus, S; Laurenti, L; Marietti, S; Metafuni, E; Piccirillo, N; Sica, S | 1 |
| Cannell, P; Cooney, J; Herrmann, R; Phillips, M; Purtill, D; Shaw, K; Sturm, M; Wright, M | 1 |
| Alsina, M; Anasetti, C; Ayala, E; Betts, BC; Fernandez, HF; Field, T; Janssen, WE; Jim, H; Kharfan-Dabaja, MA; Kim, J; Locke, FL; Nishihori, T; Ochoa, L; Perez, L; Perkins, J; Pidala, J; Tomblyn, M; Veerapathran, A; Xu, M | 1 |
| Alyea, EP; Antin, JH; Armand, P; Bindra, B; Blazar, BR; Cutler, C; Ho, VT; Kim, HT; Koreth, J; McDonough, SM; Ritz, J; Soiffer, RJ; Stevenson, KE | 1 |
| Aoi, J; Fukushima, S; Ihn, H; Inoue, Y; Jinnin, M; Makino, T; Masuguchi, S; Ogata, A; Sakai, K | 1 |
| Bucher, CM; Passweg, JR | 1 |
| Fujisawa, S; Fujita, H; Kanamori, H; Kanda, Y; Kobayashi, T; Mori, T; Nakaseko, C; Nannya, Y; Ohashi, K; Okamoto, S; Sakamaki, H; Sakura, T; Takahashi, S; Tanaka, M; Yokota, A | 1 |
| Caballero, D; Chopra, R; Craddock, C; García-Conde, J; Goldstone, AH; Hunter, A; Kottaridis, PD; Leon, A; Linch, DC; Mackinnon, S; Martino, R; Milligan, DW; Parker, A; Pérez-Simón, JA; San Miguel, JF; Schey, S; Sierra, J; Sureda, A; Urbano-Ispizua, A; Yong, K | 1 |
| Fischer, G; Greinix, HT; Höcker, P; Kalhs, P; Keil, F; Lechner, K; Mayr, W; Mitterbauer, M; Worel, N | 1 |
| Daly, AS; Hasegawa, W; Jamal, H; Kiss, TL; Kotchetkova, N; Lipton, JH; Messner, HA; Yi, QL | 1 |
| Flowers, ME; Leisenring, W; Maloney, DG; Maris, MB; Martin, PJ; Mielcarek, M; Sandmaier, BM; Storb, R | 1 |
| Bravo-Hernández, G; Estrada, E; Gómez-Rangel, D; López-Martínez, B; Manuel Hernández, J; Marín-López, A; Ruiz-Argüelles, GJ | 1 |
| Kawano, Y; Koga, Y; Nagatoshi, Y; Okamura, J | 1 |
| Höffken, K; Issa, MC; Kasper, C; Mügge, LO; Sayer, HG; Schilling, K; Scholl, S | 1 |
| Chan, G; Foss, FM; Gorgun, G; Grodman, H; Lawrence, D; Mahajan, A; Miller, KB; Relias, V; Roberts, TF; Schenkein, DP; Sprague, K | 1 |
| Alyea, E; Antin, JH; Cutler, C; Fisher, DC; Ho, V; Hochberg, E; Kim, HT; Lee, SJ; Levin, J; Miklos, D; Soiffer, RJ; Sonis, S | 1 |
| Andresen, S; Bolwell, B; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Diaconescu, R; Maloney, DG; Maris, MB; McSweeney, P; Parikh, CR; Sandmaier, BM; Schrier, RW; Sorror, ML; Storb, R; Storer, B | 1 |
| Chen, H; Chen, Y; Han, W; Huang, XJ; Jiang, Q; Liu, D; Liu, K; Lu, D; Xu, L; Zhang, Y | 1 |
| Bilaniuk, LT; Fisher, MJ; Khademian, ZP; Simon, EM; Zimmerman, RA | 1 |
| Cetkovsky, P; Maalouf, J; Pohlreich, D; Vitek, A | 1 |
| Fujimori, Y; Hara, H; Itoi, H; Itsukuma, T; Kai, S; Misawa, M; Nakajima, T; Nishioka, K; Nomura, K; Ogawa, H; Okada, M; Takatsuka, H; Toda, A; Wakae, T | 1 |
| Iida, H; Kitaori, K; Kohno, A; Matsuo, K; Morishita, Y; Ozeki, K; Sakamaki, H; Sao, H; Yokozawa, T | 1 |
| Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Giralt, S; Hosing, C; Khouri, IF; Korbling, M; Lekakis, L; Martin, T; Shpall, EJ | 1 |
| Jiang, XF; Sheng, BJ | 1 |
| Bensinger, W | 1 |
| Hamaguchi, M; Iida, H; Kohno, A; Matsuo, K; Miyamura, K; Morishita, Y; Murata, M; Narimatsu, H; Oba, T; Sawa, M; Terakura, S; Uchida, T; Watanabe, M | 1 |
| Alyea, E; Antin, JH; Cutler, C; Ho, VT; Koreth, J; Li, S; Soiffer, RJ | 1 |
| Inamoto, Y; Kodera, Y; Kuwatsuka, Y; Miyamura, K; Oba, T; Sugimoto, K; Takahashi, T; Terakura, S; Tsujimura, A; Yasuda, T | 1 |
| Adachi, N; Fujita, N; Goto, H; Hasegawa, D; Hirota, Y; Inukai, T; Ishida, H; Kanegane, H; Kato, K; Kigasawa, H; Kikuchi, A; Kikuta, A; Kishimoto, T; Kobayashi, M; Koike, K; Kuroda, H; Matsuzaki, A; Nagatoshi, Y; Nakamura, K; Nakano, T; Nakazawa, Y; Okada, K; Osugi, Y; Tanaka, R; Tokuda, K; Tsuchida, M; Uoshima, N; Watanabe, A; Yabe, H; Yagasaki, H; Yoshihara, T | 1 |
| Abe, Y; Imataki, O; Kawakami, K; Kusafuka, K; Tamai, Y | 1 |
| Hara, M; Hino, M; Hori, A; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Mori, S; Ohashi, Y; Saito, AM; Suzuki, R; Takami, A; Takaue, Y; Takemoto, Y; Taniguchi, S; Yamaguchi, M; Yoshida, T | 1 |
| Aisa, Y; Ikeda, Y; Mihara, A; Mori, T; Nakazato, T; Okamoto, S; Shimizu, T; Yamane, A; Yamazaki, R | 1 |
| Fujioka, T; Hasei, H; Iiboshi, Y; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Ogawa, H; Soma, T; Tamaki, H; Taniguchi, Y; Tazuke, Y; Yoshihara, S | 1 |
| Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Styler, MJ; Topolsky, D | 1 |
| Alegre, A; Benet, I; Besalduch, J; Brunet, S; Carreras, E; de la Rubia, J; Díaz, MA; Domingo-Albós, A; García-Conde, J; Hernández, F; Moraleda, JM; Ojeda, E; Petit, J; Rozman, C; Sanz, G; Solano, C; Urbano-Ispizua, A; Vivancos, P | 1 |
| Appelbaum, FR; Bensinger, WI; Benyunes, M; Buckner, CD; Clift, R; Demirer, T; Lee, M; Martin, P; Rowley, S; Schiller, G; Shannon-Dorcy, K; Storb, R | 1 |
| Adams, PT; Jacobson, P; Ratanatharathorn, V; Scalzo, A; Silver, SM; Uberti, JP | 1 |
| Connaghan, DG; Devine, SM; Dix, SP; Fitzsimmons, WE; Geller, RB; Heffner, LT; Hillyer, CD; Holland, HK; Keller, J; Lin, LB; Maher, RM; Maurer, D; O'Toole, K; Rodey, GE; Wingard, JR; Winton, EF | 1 |
| Antin, JH; Avalos, B; Buell, DN; Christiansen, NP; Devine, SM; Fay, JW; Fitzsimmons, WE; Herzig, RH; Karanes, C; Klein, JL; Litzow, MR; Longo, WL; Maher, RM; Nademanee, A; Nash, RA; Petersen, FB; Przepiorka, D; Ratanatharathorn, V; Storb, R; van der Jagt, R; Weisdorf, D; Wingard, JR; Wolff, SN | 1 |
| Dieckman, K; Fischer, G; Greinix, HT; Kalhs, P; Keil, F; Lechner, K; Leitner, G; Malzer, R; Rabitsch, W; Reiter, E | 1 |
| Dräger, LM; Huijgens, PC; Jonkhoff, AR; Schuurhuis, GJ; Teule, GJ; Van Leeuwen-Stok, EA; Visser-Platier, AW | 1 |
| Alvarez, MA; Falcon, M; García-Castellano, JM; Gomez, P; Herrera, C; Martin, C; Martinez, F; Roman, J; Serrano, J; Torres, A | 1 |
| Chan, KW; Danielson, M; Mattewada, V; Mullen, CA; Petropoulos, D; Przepiorka, D | 1 |
| Abboud, C; Constine, L; DiPersio, J; Duerst, R; Liesveld, J; Linder, T; McKenna, B; Packman, C; Rapoport, A; Rowe, J; Silverman, W; Swift, S; Wedow, L; Zwetsch, L | 1 |
| Chessells, JM; Hann, IM; Rees, H; Webb, DK | 1 |
| Anderlini, P; Andersson, BS; Braunschweig, I; Champlin, R; Claxton, D; Cleary, K; Donato, M; Fischer, H; Folloder, J; Fritsche, H; Gajewski, J; Giralt, S; Ippoliti, C; Khouri, IF; Mehra, R; Przepiorka, D; Saliba, R; Tonai, R; Ueno, NT; van Besien, K | 1 |
| Elonen, E; Juvonen, E; Parkkali, T; Ruutu, T; Volin, L | 1 |
| Chakrabarti, S; Chakraverty, RK; Chopra, R; de Elvira, MC; Devereux, S; Goldstone, AH; Hale, G; Kottaridis, PD; Linch, DC; Mackinnon, S; Mahendra, P; Marsh, JC; Milligan, DW; Morgan, GJ; Peggs, K; Pettengell, R; Robinson, S; Schey, S; Verfuerth, S; Waldmann, H; Williams, CD | 1 |
| Ilan, Y; Menachem, Y; Nagler, A | 1 |
| Ancín, I; Berlanga, J; Ferrá, C; Gallardo, D; Gonzalez, JR; Grañena, A; Peris, J; Virgili, N | 1 |
| Alessandrino, PE; Bacigalupo, A; Barbanti, M; Bosi, A; Bruno, B; Bruzzi, P; di Bartolomeo, P; Guidi, S; Lamparelli, T; Oneto, R; Sacchi, N; Van Lint, MT | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
9 review(s) available for methotrexate and Hematologic Malignancies
| Article | Year |
|---|---|
The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis.
Topics: Disease-Free Survival; Hematologic Neoplasms; Humans; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Genetic; Survival | 2019 |
Primary CNS lymphoma and neurologic complications of hematologic malignancies.
Topics: Antimetabolites, Antineoplastic; Central Nervous System Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Hematologic Neoplasms; Humans; Leukemia; Lymphoma; Methotrexate | 2015 |
The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Methotrexate; Mouth Mucosa; Myeloablative Agonists; Severity of Illness Index; Stomatitis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2016 |
MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Hematologic Neoplasms; Humans; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Genetic | 2016 |
Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs.
Topics: Acute Kidney Injury; Adult; Antimetabolites, Antineoplastic; Brain Neoplasms; Drug Interactions; Gemfibrozil; Hematologic Neoplasms; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Risk Factors | 2008 |
Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities.
Topics: Animals; Antineoplastic Agents; Cytarabine; Hematologic Neoplasms; Humans; Injections, Spinal; Methotrexate; Nervous System Diseases | 2009 |
Advances in individual prediction of methotrexate toxicity: a review.
Topics: Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Hematologic Neoplasms; Humans; Methotrexate; Pharmacogenetics; Polymorphism, Genetic | 2009 |
Influence of one human leukocyte antigen mismatch on outcome of allogeneic bone marrow transplantation from related donors.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclosporine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Histocompatibility Testing; HLA Antigens; Host vs Graft Reaction; Humans; Infections; Male; Methotrexate; Middle Aged; Parents; Risk; Siblings; Survival Analysis; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration.
Topics: Bone Marrow Transplantation; Disease Management; Dose-Response Relationship, Drug; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Methotrexate; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Time Factors; Transplantation, Homologous | 2006 |
45 trial(s) available for methotrexate and Hematologic Malignancies
| Article | Year |
|---|---|
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
Topics: Adolescent; Adult; Aged; Calcineurin Inhibitors; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combination; Female; Germany; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Tacrolimus; Time Factors; Transplantation Conditioning; United States; Young Adult | 2022 |
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
Topics: Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Methotrexate; Sphingosine-1-Phosphate Receptors | 2023 |
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchiolitis Obliterans Syndrome; Cyclophosphamide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Methotrexate; Mycophenolic Acid; Neoplasm Recurrence, Local; Tacrolimus; Unrelated Donors | 2023 |
Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R.
Topics: Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Illinois; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Molecular Targeted Therapy; Neoplasms; Patient Selection; Prognosis; Receptor, IGF Type 1; Risk Assessment; Survival Analysis | 2019 |
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cyclosporine; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Patient Reported Outcome Measures; Peripheral Blood Stem Cell Transplantation; T-Lymphocytes; Tacrolimus; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Young Adult | 2020 |
Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Young Adult | 2020 |
Evaluation of time to clearance of high-dose methotrexate using the ARK immunoassay in pediatric hematology/oncology patients: A single-center experience.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Dose-Response Relationship, Drug; Female; Fluorescence Polarization Immunoassay; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunoassay; Male; Methotrexate; Monitoring, Physiologic; Prognosis; Retrospective Studies | 2021 |
Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: A comparative randomized double-blind controlled trial.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Double-Blind Method; Female; Hematologic Neoplasms; Humans; Hydrocortisone; Infant; Infant, Newborn; Male; Methotrexate; Nausea; Ondansetron; Prospective Studies; Vomiting | 2021 |
A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cyclosporine; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Methylprednisolone; Middle Aged; Transplantation, Homologous; Young Adult | 2018 |
Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Pilot Projects; Sirolimus; Survival Rate; Tacrolimus; Unrelated Donors | 2019 |
Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Chronic Disease; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Methotrexate; Severity of Illness Index; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors | 2015 |
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Topics: Adult; Bortezomib; Busulfan; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Survival Analysis; Tacrolimus; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Vidarabine | 2015 |
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Premedication; Sirolimus; Tacrolimus; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
Topics: Adolescent; Adult; Anemia, Aplastic; Child; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation, Homologous | 2009 |
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Topics: Acute Disease; Administration, Oral; Adult; Age Factors; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Sex Factors; Sirolimus; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Topics: Adolescent; Adult; Antilymphocyte Serum; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Prospective Studies; Regression Analysis; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Living Donors; Male; Methotrexate; Pyrazines; Stem Cell Transplantation; Survival Rate; Tacrolimus; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Female; Hematologic Neoplasms; Humans; Ifosfamide; Lymphopenia; Male; Methotrexate; Middle Aged; Mucormycosis; Neutropenia; Pilot Projects | 2010 |
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
Topics: Adolescent; Adult; Antilymphocyte Serum; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Recurrence; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
Topics: Acute Disease; Adult; Calcineurin Inhibitors; Chronic Disease; Combined Modality Therapy; Drug Resistance; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Mesenchymal Stem Cell Transplantation; Methotrexate; Middle Aged; Morbidity; Steroids; Survival Analysis; Young Adult | 2012 |
A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Case-Control Studies; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Quality of Life; Sirolimus; Survival Rate; T-Lymphocytes, Regulatory; Tacrolimus; Transplantation, Homologous; Treatment Outcome; Young Adult | 2012 |
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
Topics: Adult; Aged; Antilymphocyte Serum; Boronic Acids; Bortezomib; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Pyrazines; Tacrolimus; Unrelated Donors | 2012 |
Prospective multicenter study of single-unit cord blood transplantation with myeloablative conditioning for adult patients with high-risk hematologic malignancies.
Topics: Adult; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Cytarabine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Prospective Studies; Risk; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors; Whole-Body Irradiation | 2013 |
Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japa
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Infant; Japan; Male; Methotrexate; Siblings; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2003 |
Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
Topics: Adult; Blood Donors; Cyclosporine; Cytomegalovirus; Graft vs Host Disease; Hematologic Neoplasms; Humans; Methotrexate; Middle Aged; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Virus Activation | 2004 |
A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.
Topics: Adolescent; Adult; Aged; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Middle Aged; Pentostatin; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2004 |
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Topics: Adult; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Sirolimus; Survival Analysis; Tacrolimus; Treatment Outcome | 2004 |
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Methotrexate; Middle Aged; Mycophenolic Acid; Prospective Studies; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2004 |
Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Child; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Premedication; Treatment Outcome | 2005 |
Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective phase II study in Japanese patients.
Topics: Adolescent; Adult; Asian People; Bone Marrow Transplantation; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; HLA Antigens; Humans; Immunosuppressive Agents; Japan; Male; Methotrexate; Middle Aged; Prospective Studies; Recurrence; Siblings; Transplantation, Homologous | 2006 |
Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.
Topics: Adult; Antilymphocyte Serum; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Middle Aged; Myeloablative Agonists; Recurrence; Risk Factors; Tacrolimus; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2006 |
Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults.
Topics: Adolescent; Adult; Aged; Cord Blood Stem Cell Transplantation; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Rate; Tacrolimus; Time Factors; Transplantation, Homologous; Treatment Outcome | 2007 |
Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.
Topics: Adolescent; Adult; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Sirolimus; Survival Rate; Tacrolimus; Tissue Donors; Transplantation Conditioning | 2007 |
Serologically HLA-DR-mismatched unrelated donors might provide a valuable alternative in allogeneic transplantation: experience from a single japanese institution.
Topics: Adolescent; Adult; Aged; Asian People; Disease-Free Survival; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; HLA-DR Antigens; Humans; Immunosuppressive Agents; Japan; Male; Methotrexate; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Tacrolimus; Transplantation, Homologous | 2007 |
Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Topics: Adult; Aged; Busulfan; Cyclosporine; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Postoperative Complications; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Cytomegalovirus Infections; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Incidence; Living Donors; Methotrexate; Methylprednisolone; Mycophenolic Acid; Myeloablative Agonists; Postoperative Complications; Tacrolimus; Transplantation Conditioning; Whole-Body Irradiation | 2008 |
Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy.
Topics: Adult; Aged; Antigens, CD34; Blood Cells; Cell Count; Cell Separation; Cyclophosphamide; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosorbent Techniques; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Prednisone; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Topics: Adult; Bone Marrow Transplantation; Disease-Free Survival; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Hyperglycemia; Hypertension; Immunosuppressive Agents; Infections; Kidney Diseases; Life Tables; Liver Diseases; Male; Methotrexate; Middle Aged; Pilot Projects; Safety; Survival Analysis; Tacrolimus; Transplantation, Homologous; Treatment Outcome | 1997 |
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Cyclosporine; Disease-Free Survival; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Hyperglycemia; Hypertension; Immunosuppressive Agents; Incidence; Male; Methotrexate; Middle Aged; Nuclear Family; Recurrence; Survival Analysis; Tacrolimus; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 1998 |
Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Child; Combined Modality Therapy; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Humans; Immunomagnetic Separation; Immunosuppressive Agents; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Transplantation, Homologous; Treatment Outcome | 1999 |
Tacrolimus for prevention of graft-versus-host disease after mismatched unrelated donor cord blood transplantation.
Topics: Antimetabolites, Antineoplastic; Child; Child, Preschool; Female; Fetal Blood; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Tacrolimus; Tissue Donors; Transplantation Conditioning | 1999 |
Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.
Topics: Acute Disease; Adolescent; Adult; Blood Transfusion; Bone and Bones; Bone Marrow Transplantation; Cause of Death; Chronic Disease; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility Testing; Hospitalization; Humans; Infections; Male; Methotrexate; Methylprednisolone; Middle Aged; Necrosis; Nuclear Family; Prospective Studies; Recurrence; Survival Rate | 2000 |
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Melphalan; Methotrexate; Microsatellite Repeats; Middle Aged; Nuclear Family; Polymerase Chain Reaction; Recurrence; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2000 |
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO).
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Bone Marrow Transplantation; Cause of Death; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infection Control; Italy; Life Tables; Male; Methotrexate; Middle Aged; Rabbits; Survival Analysis; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous | 2001 |
72 other study(ies) available for methotrexate and Hematologic Malignancies
| Article | Year |
|---|---|
High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B; Egypt; Female; Hematologic Neoplasms; Humans; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Genetic; Prospective Studies; Young Adult | 2022 |
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; Disease Progression; Female; Hematologic Neoplasms; Hospitalization; Humans; Incidence; Lenalidomide; Male; Methotrexate; Pneumonia; Pneumonia, Pneumococcal; Rituximab; Thalidomide | 2022 |
Isolated CNS relapse of blastic plasmacytoid dendritic cell neoplasm.
Topics: Adult; Central Nervous System Neoplasms; Dendritic Cells; Hematologic Neoplasms; Humans; Injections, Spinal; Male; Methotrexate; Myeloproliferative Disorders; Recurrence | 2022 |
Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children.
Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Male; Methotrexate; Retrospective Studies; Survival Rate; Transplantation Conditioning; Unrelated Donors | 2020 |
Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies.
Topics: Adult; Aged; Anti-Bacterial Agents; Carbapenems; Cefepime; Disease-Free Survival; Female; Glycopeptides; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult | 2021 |
Risk factors for high-dose methotrexate-induced nephrotoxicity.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Female; Hematologic Neoplasms; Humans; Kidney Diseases; Male; Methotrexate; Middle Aged; Retrospective Studies; Risk Factors; Uric Acid; Young Adult | 2021 |
Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience.
Topics: Adult; Allografts; Antilymphocyte Serum; Cyclosporine; Disease-Free Survival; Dose-Response Relationship, Immunologic; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Infections; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Proportional Hazards Models; Recurrence; Retrospective Studies; T-Lymphocytes; Unrelated Donors | 2021 |
Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning.
Topics: Alleles; Antimetabolites, Antineoplastic; Biomarkers; Child; Genotype; Hematologic Neoplasms; Humans; Machine Learning; Methotrexate; Nomograms; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Reproducibility of Results; Risk Assessment; ROC Curve | 2021 |
Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Hematologic Neoplasms; Humans; Lymphoma, Mantle-Cell; Male; Mercaptopurine; Methotrexate; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies; Treatment Outcome; Vincristine; Young Adult | 2021 |
Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.
Topics: Adolescent; Age Distribution; Analysis of Variance; Child; Child, Preschool; Cytarabine; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hand-Foot Syndrome; Hematologic Neoplasms; Humans; Incidence; Infusions, Intravenous; Male; Methotrexate; Multivariate Analysis; Odds Ratio; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Distribution | 2017 |
Current Use and Trends in Hematopoietic Cell Transplantation in the United States.
Topics: Adult; Alemtuzumab; Antilymphocyte Serum; Calcineurin Inhibitors; Child; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histocompatibility Testing; Humans; Methotrexate; Myeloablative Agonists; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous | 2017 |
Evaluation of standardized triple intrathecal therapy toxicity in oncohematological adult patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Hematologic Neoplasms; Humans; Hydrocortisone; Injections, Spinal; Male; Methotrexate; Middle Aged; Prospective Studies; Young Adult | 2017 |
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Topics: Adult; Aged; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Female; Hematologic Neoplasms; Humans; Male; Methotrexate; Middle Aged; Proton Pump Inhibitors; Ranitidine; Retrospective Studies; Time Factors | 2018 |
Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Gas Chromatography-Mass Spectrometry; Genotype; Hematologic Neoplasms; Humans; Kidney; Liver; Liver-Specific Organic Anion Transporter 1; Male; Metabolomics; Methotrexate; Middle Aged; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies; Renal Elimination; Urinalysis; Young Adult | 2018 |
Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation.
Topics: Acute Disease; Adult; Aged; Area Under Curve; Biomarkers, Tumor; Calcineurin Inhibitors; Case-Control Studies; Cyclosporine; Exosomes; Female; Gene Expression Profiling; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; MicroRNAs; Middle Aged; Myeloablative Agonists; ROC Curve; Survival Analysis; Tacrolimus; Transplantation, Homologous | 2018 |
Characteristics of methotrexate-induced stroke-like neurotoxicity.
Topics: Antimetabolites, Antineoplastic; Blood Coagulation; Blood Coagulation Tests; Child; Child, Preschool; Diagnosis, Differential; Female; Hematologic Neoplasms; Humans; Leukoencephalopathies; Male; Methotrexate; Neurotoxicity Syndromes; Retrospective Studies; Stroke | 2018 |
Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.
Topics: Adolescent; Antibiotic Prophylaxis; Antifungal Agents; Antimetabolites, Antineoplastic; Aspergillosis; Cheilitis; Child; Child, Preschool; Dermatitis, Photoallergic; Drug Therapy, Combination; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Leukemia, Megakaryoblastic, Acute; Male; Methotrexate; Pyrimidines; Skin; Treatment Outcome; Triazoles; Voriconazole | 2013 |
Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Busulfan; Drug Administration Schedule; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Transfusion; Male; Methotrexate; Middle Aged; Pilot Projects; Secondary Prevention; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Child; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Morbidity; Mycophenolic Acid; Neoplasm Recurrence, Local; Prognosis; Survival Rate; Transplantation, Homologous; Unrelated Donors; Young Adult | 2013 |
[Blastic plasmacytoid dendritic cell neoplasm revealed by ecchymotic lesions on the face].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Biopsy; Bone Marrow Transplantation; CD4 Antigens; CD56 Antigen; Combined Modality Therapy; Dendritic Cells; Dexamethasone; Ecchymosis; Facial Dermatoses; Hematologic Neoplasms; Humans; Immunophenotyping; Male; Methotrexate; Proto-Oncogene Proteins; Transplantation, Autologous | 2014 |
Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Clinical Trials as Topic; Genotype; Hematologic Neoplasms; Humans; Infant; Liver Diseases; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Pharmacogenetics; Polymorphism, Genetic; Precision Medicine | 2014 |
Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Female; Genotype; Hematologic Neoplasms; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk; Young Adult | 2014 |
Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Aged; Blood Platelets; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neutrophils; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Tissue Donors; Transplantation, Homologous | 2015 |
Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease.
Topics: Acute Disease; Adult; Biomarkers, Tumor; Canada; Chronic Disease; Cohort Studies; Cyclosporine; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Single Nucleotide; Prognosis; Survival Rate; Young Adult | 2015 |
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Outcome Assessment, Health Care; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Survival Analysis; Transplantation Conditioning; Unrelated Donors; Vidarabine; Young Adult | 2015 |
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
Topics: Acute Kidney Injury; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Costs; Drug Evaluation; Female; gamma-Glutamyl Hydrolase; Hematologic Neoplasms; Humans; Inactivation, Metabolic; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Methotrexate; Osteosarcoma; Recombinant Proteins; Recovery of Function; Retrospective Studies; Young Adult | 2015 |
CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.
Topics: Acute Disease; Adult; Aged; Allografts; Aminosalicylic Acids; Benzenesulfonates; Bone Marrow Transplantation; CD4-Positive T-Lymphocytes; Dendritic Cells; Female; Glucocorticoids; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Culture Test, Mixed; Male; Methotrexate; Middle Aged; Nuclear Receptor Subfamily 1, Group F, Member 3; Peripheral Blood Stem Cell Transplantation; Phosphorylation; Prospective Studies; Protein Processing, Post-Translational; Receptors, Interleukin-6; Sirolimus; STAT3 Transcription Factor; Th17 Cells; TOR Serine-Threonine Kinases | 2015 |
Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Topics: Adolescent; Adult; Child; Cyclosporine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Transplantation, Homologous; Young Adult | 2015 |
Rechallenging With Intrathecal Methotrexate After Developing Subacute Neurotoxicity in Children With Hematologic Malignancies.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Consolidation Chemotherapy; Female; Hematologic Neoplasms; Humans; Induction Chemotherapy; Injections, Spinal; Maintenance Chemotherapy; Male; Methotrexate; Neurotoxicity Syndromes; Retrospective Studies; Young Adult | 2016 |
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Killer Cells, Natural; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pregnancy; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous | 2016 |
Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hematocrit; Hematologic Neoplasms; Humans; Male; Methotrexate; Middle Aged; Models, Biological; Nonlinear Dynamics; Qatar; Retrospective Studies; Tissue Distribution; Young Adult | 2017 |
Influence of ADORA2A gene polymorphism on leukoencephalopathy risk in MTX-treated pediatric patients affected by hematological malignancies.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Infant; Leukoencephalopathies; Male; Methotrexate; Polymorphism, Single Nucleotide; Receptor, Adenosine A2A; Retrospective Studies; Risk | 2016 |
Evaluation of standardized triple intrathecal therapy toxicity in oncohematological pediatric patients.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cohort Studies; Cytarabine; Female; Headache; Hematologic Neoplasms; Humans; Injections, Spinal; Male; Methotrexate; Prospective Studies; Vomiting | 2017 |
Outcome of bone marrow transplantation from HLA-identical sibling donor in children with hematological malignancies using methotrexate alone as prophylaxis for graft-versus-host disease.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Child; Child, Preschool; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; HLA Antigens; Humans; Incidence; Infant; Living Donors; Male; Methotrexate; Retrospective Studies; Risk Factors; Siblings; Survival Rate | 2008 |
Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Retrospective Studies; Survival Analysis; Survivors; Tacrolimus; Whole-Body Irradiation; Young Adult | 2008 |
Tacrolimus with mini-methotrexate as prophylaxis for graft-versus-host disease in pediatric patients after allogeneic peripheral blood stem cell transplant or bone marrow transplant.
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Methotrexate; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Rate; Tacrolimus; Transplantation, Homologous; Treatment Outcome; Young Adult | 2008 |
Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study.
Topics: Acute Disease; Clinical Trials, Phase III as Topic; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Methotrexate; Organ Specificity; Postoperative Complications; Randomized Controlled Trials as Topic; Retrospective Studies; Skin Diseases; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous | 2009 |
Ocular findings after allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Child; Cyclosporine; Eye Diseases; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Intraocular Pressure; Male; Methotrexate; Middle Aged; Ophthalmoscopy; Retrospective Studies; Transplantation, Homologous; Visual Acuity | 2009 |
Interpreting registry-derived drug studies: does societal context matter?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Hematologic Neoplasms; Humans; Methotrexate; Registries; Risk Factors; Severity of Illness Index; Single-Payer System; Skin Neoplasms; Socioeconomic Factors; Sweden; Tumor Necrosis Factor-alpha; United States | 2009 |
Influence of lymphocyte recovery on outcome of haploidentical transplantation for hematologic malignancies.
Topics: Adolescent; Adult; Child; Cyclosporine; Female; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Methotrexate; Middle Aged; Transplantation, Homologous; Treatment Outcome; Young Adult | 2009 |
Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Topics: Adult; Antilymphocyte Serum; Calcineurin Inhibitors; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Methotrexate; Middle Aged; Retrospective Studies; Risk Factors; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Transplantation Conditioning; Transplantation, Homologous; Young Adult | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.
Topics: Adolescent; Adult; Aged; Calcineurin Inhibitors; Child; Child, Preschool; Cyclosporine; Drug Evaluation; Drug Therapy, Combination; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Standard of Care; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2011 |
Predictors of bone loss in childhood hematologic malignancies: a prospective study.
Topics: Absorptiometry, Photon; Age Factors; Anthropometry; Body Mass Index; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Child; Child, Preschool; Dexamethasone; Epidemiologic Methods; Female; Glucocorticoids; Hematologic Neoplasms; Hip Joint; Humans; Life Style; Lumbar Vertebrae; Male; Methotrexate; Parathyroid Hormone; Vitamin D | 2012 |
T-cell depletion in GVHD: less is more?
Topics: Adolescent; Adult; Antilymphocyte Serum; Chronic Disease; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Recurrence; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Child; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Retrospective Studies; Tacrolimus; Time Factors; Tissue Donors; Transplantation, Homologous | 2012 |
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Genetic; Reduced Folate Carrier Protein; Young Adult | 2012 |
Case of blastic plasmacytoid dendritic cell neoplasm.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Dendritic Cells; Dexamethasone; Doxorubicin; Hematologic Neoplasms; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Skin Neoplasms; Stem Cell Transplantation; Vincristine | 2012 |
Towards rational graft-versus-host disease prophylaxis.
Topics: Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Methotrexate; Neoplasm Recurrence, Local; Sirolimus; Tacrolimus | 2012 |
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Infections; Life Tables; Lymphoproliferative Disorders; Male; Melphalan; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Spain; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; United Kingdom; Vidarabine | 2002 |
Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning.
Topics: ABO Blood-Group System; Adolescent; Adult; Aged; Anemia, Hemolytic; B-Lymphocytes; Blood Group Incompatibility; Carcinoma, Renal Cell; Erythrocyte Transfusion; Female; Graft vs Host Disease; Hematologic Neoplasms; Hemolysis; Humans; Immunosuppressive Agents; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Peripheral Blood Stem Cell Transplantation; Prevalence; Rh-Hr Blood-Group System; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2002 |
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Topics: Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Incidence; Intestines; Life Tables; Liver; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Severity of Illness Index; Skin; Survival Analysis; Time Factors; Tissue Donors; Transplantation Conditioning; Vidarabine; Washington; Whole-Body Irradiation | 2003 |
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Transfusion; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Platelet Transfusion; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Male; Methotrexate; Methylprednisolone; Middle Aged; Mycophenolic Acid; Patient Selection; Postoperative Complications; Recurrence; Renal Dialysis; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2005 |
Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children.
Topics: Adolescent; Antimetabolites, Antineoplastic; Aphasia; Brain; Brain Diseases; Child; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Hematologic Neoplasms; Hemiplegia; Humans; Male; Methotrexate; Neurotoxins | 2005 |
Decreased risk of acute gastrointestinal toxicity when substituting methotrexate with mycophenolate mofetil in the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning regimens.
Topics: Adult; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Mucositis; Mycophenolic Acid; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2006 |
Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
Topics: Adult; Bone Marrow; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Myeloablative Agonists; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
[Clinical study of unrelated umbilical cord blood transplantation in 32 children patients].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclosporine; Graft vs Host Disease; Hematologic Neoplasms; Humans; Methotrexate; Survival Rate; Transplantation Conditioning | 2006 |
Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents.
Topics: Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chimerism; Drug Therapy, Combination; Genetic Diseases, Inborn; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Kaplan-Meier Estimate; Methotrexate; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Tacrolimus; Transplantation, Homologous; Treatment Outcome | 2007 |
[Three cases of necrotizing pneumonia by pseudomonas aeruginosa infection in hematological malignancy, including dead and alive cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fatal Outcome; Hematologic Neoplasms; Humans; Male; Methotrexate; Methylprednisolone; Middle Aged; Necrosis; Neutropenia; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Severity of Illness Index | 2007 |
Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
Topics: Adult; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Leukemia; Leukocyte Count; Lymphoma; Male; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Neutrophils; Probability; Tacrolimus; Transplantation Conditioning | 2007 |
Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topics: Actuarial Analysis; Acute Disease; Adult; Anti-Infective Agents; Bone Marrow Transplantation; Busulfan; Cause of Death; Critical Care; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Hematologic Neoplasms; Hepatic Veno-Occlusive Disease; Histocompatibility; HLA-DR Antigens; Humans; Immunosuppressive Agents; Infections; Lymphocyte Depletion; Male; Methotrexate; Middle Aged; Risk; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 1996 |
Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Bone Marrow; Catheterization, Central Venous; Child; Cyclosporine; Female; Filgrastim; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Lenograstim; Leukapheresis; Leukocyte Count; Male; Methotrexate; Middle Aged; Neutrophils; Platelet Count; Recombinant Proteins; Retreatment; Retrospective Studies; Safety; Transplantation, Homologous; Treatment Outcome | 1996 |
Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Hyperbilirubinemia; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Prognosis; Recurrence; Renal Insufficiency; Tacrolimus; Transplantation, Homologous | 1997 |
Experience with allogeneic and syngeneic blood stem cell transplantation in patients with hematological malignancies.
Topics: Adult; Cyclosporine; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Transplantation Conditioning; Transplantation, Homologous | 1998 |
Cell cycle dependency of 67gallium uptake and cytotoxicity in human cell lines of hematological malignancies.
Topics: Antineoplastic Agents; Biological Transport; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Drug Interactions; Flow Cytometry; Gallium Radioisotopes; Hematologic Neoplasms; HL-60 Cells; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Neoplasm Proteins; Neoplastic Stem Cells; Prednisolone; Radiopharmaceuticals; Receptors, Transferrin; Tumor Cells, Cultured | 1998 |
Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
Topics: Adolescent; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Calcium Channel Blockers; Cause of Death; Child; Child, Preschool; Cyclosporine; Drug Therapy, Combination; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Life Tables; Male; Methotrexate; Methylprednisolone; Middle Aged; Nifedipine; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Wiskott-Aldrich Syndrome | 1999 |
Are glomerular filtration rate estimations necessary before high dose methotrexate?
Topics: Antimetabolites, Antineoplastic; Child; Cost-Benefit Analysis; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Humans; Kidney Diseases; Male; Methotrexate | 1999 |
Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.
Topics: Acute Disease; Adolescent; Adult; Alleles; Bone Marrow Transplantation; Female; Filgrastim; Genes, MHC Class II; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Histocompatibility; HLA-DQ Antigens; HLA-DR Antigens; Humans; Male; Methotrexate; Middle Aged; Recombinant Proteins; Risk Factors; Survival Rate; Tacrolimus; Tissue Donors; Treatment Outcome | 2000 |
Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment.
Topics: Adolescent; Adult; Cholestasis, Intrahepatic; Cyclosporine; Drug Evaluation; Drug Resistance; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Function Tests; Male; Methotrexate; Prednisone; Tacrolimus; Transplantation, Homologous; Treatment Outcome | 2001 |
Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cause of Death; Cyclosporine; Female; Gastrointestinal Hemorrhage; Graft vs Host Disease; Hematologic Neoplasms; Humans; Hypertension; Infections; Male; Methotrexate; Middle Aged; Musculoskeletal Diseases; Prednisone; Retrospective Studies; Survival Analysis; Therapeutic Equivalency; Transplantation, Homologous | 2001 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |